Format

Send to

Choose Destination
See comment in PubMed Commons below
J Control Release. 2010 Oct 15;147(2):154-62. doi: 10.1016/j.jconrel.2010.05.015. Epub 2010 May 19.

Mesenchymal stem cells: a promising targeted-delivery vehicle in cancer gene therapy.

Author information

1
Institute of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, PR China.

Abstract

The targeting drug delivery systems (TDDS) have attracted extensive attention of researchers in recent years. More and more drug/gene targeted delivery carriers, such as liposome, magnetic nanoparticles, ligand-conjugated nanoparticles, microbubbles, etc., have been developed and under investigation for their application. However, the currently investigated drug/gene carriers have several disadvantages, which limit their future use in clinical practice. Therefore, design and development of novel drug/gene delivery vehicles has been a hot area of research. Recent studies have shown the ability of mesenchymal stem cells (MSCs) to migrate towards and engraft into the tumor sites, which make them a great hope for efficient targeted-delivery vehicles in cancer gene therapy. In this review article, we examine the promising of using mesenchymal stem cells as a targeted-delivery vehicle for cancer gene therapy, and summarize various challenges and concerns regarding these therapies.

PMID:
20493219
DOI:
10.1016/j.jconrel.2010.05.015
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center